With this information, the construction of hybrid platforms that combine LSEC targeting as well as pharmaceutical enhancers of APC tolerogenic activity, enhancement of Treg generation, and stable FoxP3+ expression should be considered for treating a range of antigen-specific immune disorders characterized by overactive immune function [66]. Here, FOXP3 is linked to immune system disorder.